Luiz Gustavo Dufner-Almeida, Laís F M Cardozo, Mariana R Schwind, Danielly Carvalho, Juliana Paula G Almeida, Andrea Maria Cappellano, Thiago G P Alegria, Santoesha Nanhoe, Mark Nellist, Maria Rita Passos-Bueno, Silvana Chiavegatto, Nasjla S Silva, Sérgio Rosemberg, Ana Paula A Pereira, Sérgio Antônio Antoniuk, Luciana A Haddad
{"title":"结节性硬化综合征患者 TSC1 和 TSC2 的分子和功能评估","authors":"Luiz Gustavo Dufner-Almeida, Laís F M Cardozo, Mariana R Schwind, Danielly Carvalho, Juliana Paula G Almeida, Andrea Maria Cappellano, Thiago G P Alegria, Santoesha Nanhoe, Mark Nellist, Maria Rita Passos-Bueno, Silvana Chiavegatto, Nasjla S Silva, Sérgio Rosemberg, Ana Paula A Pereira, Sérgio Antônio Antoniuk, Luciana A Haddad","doi":"10.3390/genes15111432","DOIUrl":null,"url":null,"abstract":"<p><p>Tuberous sclerosis complex (TSC) is an autosomal dominant neurodevelopmental disorder and multisystem disease caused by pathogenic DNA alterations in the <i>TSC1</i> and <i>TSC2</i> tumor suppressor genes. A molecular genetic diagnosis of TSC confirms the clinical diagnosis, facilitating the implementation of appropriate care and surveillance. <i>TSC1</i> and <i>TSC2</i> encode the core components of the TSC1/2 complex (TSC1/2), a negative regulator of the mechanistic target of rapamycin (MTOR) complex 1 (TORC1). Functional analysis of the effects of <i>TSC1</i> and <i>TSC2</i> variants on TORC1 activity can help establish variant pathogenicity. We searched for pathogenic alterations to <i>TSC1</i> and <i>TSC2</i> in DNA isolated from 116 individuals with a definite clinical diagnosis of TSC. Missense variants and in-frame deletions were functionally assessed. Pathogenic DNA alterations were identified in 106 cases (91%); 18 (17%) in <i>TSC1</i> and 88 (83%) in <i>TSC2</i>. Of these, 35 were novel. Disruption of TSC1/2 activity was demonstrated for seven <i>TSC2</i> variants. Molecular diagnostics confirms the clinical diagnosis of TSC in a large proportion of cases. Functional assessment can help establish variant pathogenicity and is a useful adjunct to DNA analysis.</p>","PeriodicalId":12688,"journal":{"name":"Genes","volume":"15 11","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11593644/pdf/","citationCount":"0","resultStr":"{\"title\":\"Molecular and Functional Assessment of <i>TSC1</i> and <i>TSC2</i> in Individuals with Tuberous Sclerosis Complex.\",\"authors\":\"Luiz Gustavo Dufner-Almeida, Laís F M Cardozo, Mariana R Schwind, Danielly Carvalho, Juliana Paula G Almeida, Andrea Maria Cappellano, Thiago G P Alegria, Santoesha Nanhoe, Mark Nellist, Maria Rita Passos-Bueno, Silvana Chiavegatto, Nasjla S Silva, Sérgio Rosemberg, Ana Paula A Pereira, Sérgio Antônio Antoniuk, Luciana A Haddad\",\"doi\":\"10.3390/genes15111432\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Tuberous sclerosis complex (TSC) is an autosomal dominant neurodevelopmental disorder and multisystem disease caused by pathogenic DNA alterations in the <i>TSC1</i> and <i>TSC2</i> tumor suppressor genes. A molecular genetic diagnosis of TSC confirms the clinical diagnosis, facilitating the implementation of appropriate care and surveillance. <i>TSC1</i> and <i>TSC2</i> encode the core components of the TSC1/2 complex (TSC1/2), a negative regulator of the mechanistic target of rapamycin (MTOR) complex 1 (TORC1). Functional analysis of the effects of <i>TSC1</i> and <i>TSC2</i> variants on TORC1 activity can help establish variant pathogenicity. We searched for pathogenic alterations to <i>TSC1</i> and <i>TSC2</i> in DNA isolated from 116 individuals with a definite clinical diagnosis of TSC. Missense variants and in-frame deletions were functionally assessed. Pathogenic DNA alterations were identified in 106 cases (91%); 18 (17%) in <i>TSC1</i> and 88 (83%) in <i>TSC2</i>. Of these, 35 were novel. Disruption of TSC1/2 activity was demonstrated for seven <i>TSC2</i> variants. Molecular diagnostics confirms the clinical diagnosis of TSC in a large proportion of cases. Functional assessment can help establish variant pathogenicity and is a useful adjunct to DNA analysis.</p>\",\"PeriodicalId\":12688,\"journal\":{\"name\":\"Genes\",\"volume\":\"15 11\",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-11-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11593644/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Genes\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.3390/genes15111432\",\"RegionNum\":3,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GENETICS & HEREDITY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genes","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.3390/genes15111432","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0
摘要
结节性硬化综合征(TSC)是一种常染色体显性神经发育障碍和多系统疾病,由 TSC1 和 TSC2 肿瘤抑制基因的 DNA 致病性改变引起。TSC的分子遗传学诊断证实了临床诊断,有助于实施适当的护理和监测。TSC1和TSC2编码TSC1/2复合体(TSC1/2)的核心成分,TSC1/2是雷帕霉素机制靶标(MTOR)复合体1(TORC1)的负调控因子。对 TSC1 和 TSC2 变体对 TORC1 活性的影响进行功能分析有助于确定变体的致病性。我们从 116 名临床诊断明确的 TSC 患者分离的 DNA 中寻找 TSC1 和 TSC2 的致病性变异。对错义变异和框架内缺失进行了功能评估。在106个病例(91%)中发现了致病性DNA改变;TSC1和TSC2中分别有18个和88个致病性DNA改变(分别占17%和83%)。其中 35 例为新病变。7个TSC2变异基因被证实破坏了TSC1/2的活性。分子诊断证实了大部分 TSC 病例的临床诊断。功能评估有助于确定变异的致病性,是 DNA 分析的有效辅助手段。
Molecular and Functional Assessment of TSC1 and TSC2 in Individuals with Tuberous Sclerosis Complex.
Tuberous sclerosis complex (TSC) is an autosomal dominant neurodevelopmental disorder and multisystem disease caused by pathogenic DNA alterations in the TSC1 and TSC2 tumor suppressor genes. A molecular genetic diagnosis of TSC confirms the clinical diagnosis, facilitating the implementation of appropriate care and surveillance. TSC1 and TSC2 encode the core components of the TSC1/2 complex (TSC1/2), a negative regulator of the mechanistic target of rapamycin (MTOR) complex 1 (TORC1). Functional analysis of the effects of TSC1 and TSC2 variants on TORC1 activity can help establish variant pathogenicity. We searched for pathogenic alterations to TSC1 and TSC2 in DNA isolated from 116 individuals with a definite clinical diagnosis of TSC. Missense variants and in-frame deletions were functionally assessed. Pathogenic DNA alterations were identified in 106 cases (91%); 18 (17%) in TSC1 and 88 (83%) in TSC2. Of these, 35 were novel. Disruption of TSC1/2 activity was demonstrated for seven TSC2 variants. Molecular diagnostics confirms the clinical diagnosis of TSC in a large proportion of cases. Functional assessment can help establish variant pathogenicity and is a useful adjunct to DNA analysis.
期刊介绍:
Genes (ISSN 2073-4425) is an international, peer-reviewed open access journal which provides an advanced forum for studies related to genes, genetics and genomics. It publishes reviews, research articles, communications and technical notes. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.